Möchten Sie immer auf dem neuesten Stand bleiben?

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into...

Delivered record-high revenues, Adjusted EBITDA1, Adjusted EBITDA per share1 since inceptionGenerated record high cash flow from operations since inceptionProvides 2026 revenues guidance of $490...

STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...

REDMOND, Wash., March 18, 2026 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”), the global leader in Pattern Discovery, today announced expanded global intellectual property...

OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights

STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...

IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as...

WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the...

Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer  Demonstration of Cyclin E1 protein overexpression as an...

BlossomHill Therapeutics Unveils New Pan-KRAS Inhibitor Programs and Announces Upcoming Presentations at AACR Annual Meeting 2026